Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1757453rdf:typepubmed:Citationlld:pubmed
pubmed-article:1757453lifeskim:mentionsumls-concept:C0023977lld:lifeskim
pubmed-article:1757453lifeskim:mentionsumls-concept:C0009011lld:lifeskim
pubmed-article:1757453lifeskim:mentionsumls-concept:C0031572lld:lifeskim
pubmed-article:1757453pubmed:dateCreated1992-2-3lld:pubmed
pubmed-article:1757453pubmed:abstractTextTwenty-six socially phobic outpatients were treated with clonazepam for the relief of symptoms. At evaluation, which took place after an average of 11.3 months of continuous treatment, 22 (84.6%) patients showed good improvement and 4 (14.4%) showed no improvement or were not recovered. The dose declined over time, from a peak mean of 2.1 mg/day to a mean of 0.94 mg/day at follow-up. Side effects are described, along with individual case descriptions that illustrate important aspects of the use of benzodiazepines for the treatment of social phobia.lld:pubmed
pubmed-article:1757453pubmed:languageenglld:pubmed
pubmed-article:1757453pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1757453pubmed:citationSubsetIMlld:pubmed
pubmed-article:1757453pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1757453pubmed:statusMEDLINElld:pubmed
pubmed-article:1757453pubmed:monthNovlld:pubmed
pubmed-article:1757453pubmed:issn0160-6689lld:pubmed
pubmed-article:1757453pubmed:authorpubmed-author:SmithR DRDlld:pubmed
pubmed-article:1757453pubmed:authorpubmed-author:DavidsonJ RJRlld:pubmed
pubmed-article:1757453pubmed:authorpubmed-author:FordS MSMlld:pubmed
pubmed-article:1757453pubmed:authorpubmed-author:PottsN LNLlld:pubmed
pubmed-article:1757453pubmed:issnTypePrintlld:pubmed
pubmed-article:1757453pubmed:volume52 Suppllld:pubmed
pubmed-article:1757453pubmed:ownerNLMlld:pubmed
pubmed-article:1757453pubmed:authorsCompleteYlld:pubmed
pubmed-article:1757453pubmed:pagination16-20lld:pubmed
pubmed-article:1757453pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:1757453pubmed:meshHeadingpubmed-meshheading:1757453-...lld:pubmed
pubmed-article:1757453pubmed:meshHeadingpubmed-meshheading:1757453-...lld:pubmed
pubmed-article:1757453pubmed:meshHeadingpubmed-meshheading:1757453-...lld:pubmed
pubmed-article:1757453pubmed:meshHeadingpubmed-meshheading:1757453-...lld:pubmed
pubmed-article:1757453pubmed:meshHeadingpubmed-meshheading:1757453-...lld:pubmed
pubmed-article:1757453pubmed:meshHeadingpubmed-meshheading:1757453-...lld:pubmed
pubmed-article:1757453pubmed:meshHeadingpubmed-meshheading:1757453-...lld:pubmed
pubmed-article:1757453pubmed:meshHeadingpubmed-meshheading:1757453-...lld:pubmed
pubmed-article:1757453pubmed:meshHeadingpubmed-meshheading:1757453-...lld:pubmed
pubmed-article:1757453pubmed:meshHeadingpubmed-meshheading:1757453-...lld:pubmed
pubmed-article:1757453pubmed:meshHeadingpubmed-meshheading:1757453-...lld:pubmed
pubmed-article:1757453pubmed:meshHeadingpubmed-meshheading:1757453-...lld:pubmed
pubmed-article:1757453pubmed:meshHeadingpubmed-meshheading:1757453-...lld:pubmed
pubmed-article:1757453pubmed:year1991lld:pubmed
pubmed-article:1757453pubmed:articleTitleLong-term treatment of social phobia with clonazepam.lld:pubmed
pubmed-article:1757453pubmed:affiliationPsychiatry Outpatient Program, Duke University Medical Center, Durham, NC 27710.lld:pubmed
pubmed-article:1757453pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1757453pubmed:publicationTypeCase Reportslld:pubmed